Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLA known ✓ | P06280 | 1/20 | 0.36 |
| ▸ | GAA known ✓ | P10253 | 1/20 | 0.36 |
| ▸ | HDAC3 known ✓ | O15379 | 1/20 | 0.35 |
| ▸ | HDAC4 known ✓ | P56524 | 1/20 | 0.35 |
| ▸ | HDAC1 known ✓ | Q13547 | 1/20 | 0.35 |
| ▸ | HDAC7 known ✓ | Q8WUI4 | 1/20 | 0.35 |
| ▸ | HDAC2 known ✓ | Q92769 | 1/20 | 0.35 |
| ▸ | HDAC10 known ✓ | Q969S8 | 1/20 | 0.35 |
| ▸ | HDAC11 known ✓ | Q96DB2 | 1/20 | 0.35 |
| ▸ | HDAC8 known ✓ | Q9BY41 | 1/20 | 0.35 |
| ▸ | HDAC6 known ✓ | Q9UBN7 | 1/20 | 0.35 |
| ▸ | HDAC9 known ✓ | Q9UKV0 | 1/20 | 0.35 |
| ▸ | HDAC5 known ✓ | Q9UQL6 | 1/20 | 0.35 |
| ▸ | ITGB3 known ✓ | P05106 | 1/20 | 0.35 |
| ▸ | ITGA2B known ✓ | P08514 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | PLG | P00747 | 1/20 | 0.50 |
| ▸ | PLAT | P00750 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL7443981 | 1.00 | TDP1 (0.52) | TDP1PLGPLATLMNAKMT2A | |
| Hydrochloric Acid SCHEMBL11285151 | 1.00 | TDP1 (0.52) | TDP1PLGPLATLMNAKMT2A | |
| Hydrochloric Acid SCHEMBL11285176 | 1.00 | TDP1 (0.52) | TDP1PLGPLATLMNAKMT2A | |
| Hydrochloric Acid SCHEMBL10894938 | 0.98 | TDP1 (0.50) | TDP1PLGPLATLMNAKMT2A | |
| SCHEMBL483347 | 0.98 | TDP1 (0.53) | TDP1PLGPLATLMNAKMT2A | |
| SCHEMBL483345 | 0.98 | TDP1 (0.53) | TDP1PLGPLATLMNAKMT2A | |
| SCHEMBL11280746 | 0.90 | TDP1 (0.46) | TDP1PLGPLATLMNAKMT2A | |
| SCHEMBL7683514 | 0.88 | TDP1 (0.46) | TDP1PLGPLATLMNAKMT2A | |
| SCHEMBL26073040 | 0.88 | TDP1 (0.46) | TDP1PLGPLATLMNAKMT2A | |
| Hydrochloric Acid SCHEMBL11276143 | 0.84 | TDP1 (0.50) | TDP1PLGPLATLMNAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1449828-B1 | Guanidinomethyl cyclohexane carboxylic acid ester derivatives | NAGASE CHEMTEX CORP (JP) | 2007-04-18 | — | — | EP | disclosed |
| US-6960681-B2 | Guanidinomethyl cyclohexane carboxylic acid ester derivatives | NAGASE CHEMTEX CORPORATION (JP) | 2005-11-01 | — | — | US | disclosed |
| US-20050075402-A1 | Guanidinomethyl cyclohexane carboxylic acid ester derivatives | TEIKOKU CHEMICAL INDUSTRIES CO., LTD. | 2005-04-07 | — | — | US | disclosed |
| US-6831190-B1 | Acts effectively in stomach, the antibacterial activity becomes weak as the compounds moves from duodenum to small intestines; do not have activity against esylhiacori, staphylococcus aureus, methacycline resistant bacterium | TEIKOKU CHEMICAL INDUSTRIES CO., LTD. (JP) | 2004-12-14 | — | — | US | disclosed |
| EP-1449828-A2 | Guanidinomethyl cyclohexane carboxylic acid ester derivatives | Nagase ChemteX Corporation (JP) | 2004-08-25 | — | — | EP | disclosed |
| EP-0989112-B1 | Intermediates for the preparation of guanidinomethyl cyclohexane carboxylic acid ester derivatives | NAGASE CHEMTEX CORP (JP) | 2004-04-14 | — | — | EP | disclosed |
| US-20020123508-A1 | 4-(4-(4-methylbenzyloxycarbonyl) phanyl)phenyl trans-4-guanidinomethylcyclohexanecarboxylate or acid addition salt thereof and cyclodextrin; use treating ulcers for example | NAGASE CHEMTEX CORPORATION (JP) | 2002-09-05 | — | — | US | disclosed |
| US-6444703-B1 | 4-(4-(4-METHYLBENZYLOXYCARBONYL) PHANYL)PHENYL TRANS-4-GUANIDINOMETHYLCYCLOHEXANECARBOXYLATE OR ACID ADDITION SALT THEREOF AND CYCLODEXTRIN; USE TREATING ULCERS FOR EXAMPLE | TEIKOKU CHEMICAL INDUSTRIES CO., LTD. (JP) | 2002-09-03 | — | — | US | disclosed |
| US-6284791-B1 | USEFUL AS AN ANTI-MICROBIAL AGAINST HELICOBACTER PYLORI | TEIKOKU CHEMICAL INDUSTRIES CO., LTD. (JP) | 2001-09-04 | — | — | US | disclosed |
| EP-0775692-B1 | GUANIDINOMETHYL CYCLOHEXANE CARBOXYLIC ESTER DERIVATIVE | TEIKOKU CHEM IND CO LTD (JP) | 2000-12-06 | — | — | EP | disclosed |
| EP-0775692-A1 | GUANIDINOMETHYL CYCLOHEXANE CARBOXYLIC ESTER DERIVATIVE | TEIKOKU CHEMICAL INDUSTRY CO., LTD. (JP) | 1997-05-28 | — | — | EP | disclosed |
| US-5294713-A | Inhibiting cell adhesion | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1994-03-15 | — | — | US | disclosed |
| EP-0529858-A1 | 2-Piperazinone compounds, their production and use | Takeda Chemical Industries, Ltd. (JP) | 1993-03-03 | — | — | EP | disclosed |
| US-4873253-A | Phenylalanine derivative and proteinase inhibitor | Okamoto, Shosuke (JP) | 1989-10-10 | — | — | US | disclosed |
| EP-0193965-B1 | NOVEL GUANIDINOMETHYLCYCLOHEXANCARBOXYLIC ACID COMPOUNDS, PROCESSES FOR PREPARING THEM, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | KANEBO, LTD. (JP) | 1988-11-30 | — | — | EP | disclosed |
| EP-0284632-A1 | Phenylalanine derivative and proteinase inhibitor | Okamoto, Shosuke (JP) | 1988-10-05 | — | — | EP | disclosed |
| US-4681895-A | Novel guanidinomethylcyclohexanecarboxylic acid compounds and anti-ulcer drug containing the same | KANEBO, LTD. (JP) | 1987-07-21 | — | — | US | disclosed |
| EP-0193965-A2 | Novel guanidinomethylcyclohexancarboxylic acid compounds, processes for preparing them, and pharmaceutical compositions containing them | KANEBO, LTD. (JP) | 1986-09-10 | — | — | EP | disclosed |
| US-4465851-A | ANTIALLERGENS, ENZYME INHIBITORS | NIPPON CHEMIPHAR CO., LTD. (JP) | 1984-08-14 | — | — | US | disclosed |
| US-4348410-A | Cyclohexane carboxylic acid derivatives | NIPPON CHEMIPHAR CO., LTD. (JP) | 1982-09-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050075402-A1 | Guanidinomethyl cyclohexane carboxylic acid ester derivatives | GCK, ADCY9, ADCY7 | GLA 46/4885GAA 61/4885HDAC3 1892/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.